🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Tiffany A. Traina

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0003-3597-0050
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.742Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772
Top 27%
0.742DataRank
Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Papers

Driven by 10 papers — median percentile 73. Top paper: “Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study”.

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

The Lancet(2023)10.1016/s0140-6736(23)01857-3
N/A
4.7DataRank · unranked
264 citations

Jonathan T. Yang, Juber Patel, Annemarie F. Shepherd, Juliana Eng, Randy Yeh +44 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Annals of Oncology(2023)10.1016/j.annonc.2023.08.004
N/A
1.7DataRank · unranked
58 citations

Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772
Top 27%
0.742DataRank
Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.159
N/A
0DataRank · unranked
450 citations

Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross +93 more

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study

Breast Cancer Research and Treatment(2022)10.1007/s10549-022-06669-2
N/A
0DataRank · unranked
17 citations

Ayca Gucalp, Sujata Patil, Marcia Edelweiss, Dara S. Ross, Pedram Razavi +17 more

Cognitive Aging in Older Breast Cancer Survivors

Cancers(2023)10.3390/cancers15123208
N/A
0DataRank · unranked
5 citations

Yuelin Li, Elizabeth Schofield, Irene Orlow, Elizabeth Ryan, Tiffany A. Traina +3 more

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

Breast Cancer Research and Treatment(2020)10.1007/s10549-020-05726-y
N/A
0DataRank · unranked
37 citations

Dulce M. Barrios, Victoria Blinder, Jacqueline Bromberg, Pamela Drullinsky, Samuel A. Funt +10 more

Traditional Chinese Medicine Herbs for Breast Cancer Prevention and Survival: A Narrative Review of Epidemiological Studies from Taiwan

Current Oncology Reports(2024)10.1007/s11912-024-01595-6
N/A
0DataRank · unranked
8 citations

Susan Chimonas, Prusha Patel, Elizabeth D. Kantor, Tiffany A. Traina, Hung‐Rong Yen +2 more

Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1063
N/A
0DataRank · unranked
4 citations

Diana G. Wang, Victoria Blinder, Jacqueline Bromberg, Pamela Drullinsky, Samuel A. Funt +10 more

Initial encoding deficits with intact memory retention in older long-term breast cancer survivors

Journal of Cancer Survivorship(2021)10.1007/s11764-021-01086-8
N/A
0DataRank · unranked
7 citations

Tim A. Ahles, Elizabeth Ryan, Elizabeth Schofield, Yuelin Li, Sunita K. Patel +4 more